Edwards Lifesciences Corporation
EW
$83.39
$0.951.15%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.37B | 4.15B | 4.18B | 4.17B | 4.16B |
| Total Depreciation and Amortization | 156.50M | 151.80M | 153.30M | 155.20M | 149.30M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.20M | -3.43B | -3.53B | -3.53B | -3.49B |
| Change in Net Operating Assets | -562.80M | -71.90M | 73.40M | -259.30M | -12.30M |
| Cash from Operations | 1.02B | 794.90M | 876.20M | 542.30M | 806.40M |
| Capital Expenditure | -212.60M | -207.00M | -243.10M | -252.40M | -290.90M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -298.20M | -1.06B | -1.06B | -1.06B | -717.60M |
| Divestitures | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Other Investing Activities | -580.50M | 3.31B | 3.64B | 3.63B | 3.91B |
| Cash from Investing | -1.09B | 2.04B | 2.34B | 2.31B | 2.90B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 214.90M | 214.70M | 167.30M | 179.50M | 184.10M |
| Repurchase of Common Stock | -897.40M | -1.21B | -1.37B | -1.06B | -1.51B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -234.30M | -158.40M | -102.20M | -103.10M | -101.20M |
| Cash from Financing | -916.80M | -1.15B | -1.30B | -983.00M | -1.42B |
| Foreign Exchange rate Adjustments | 2.70M | -47.80M | 11.20M | 38.60M | -15.80M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -988.60M | 1.63B | 1.92B | 1.91B | 2.27B |